IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 933 shares of the company’s stock after selling 722 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in IDEXX Laboratories were worth $466,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. LRI Investments LLC grew its position in shares of IDEXX Laboratories by 21.7% during the 2nd quarter. LRI Investments LLC now owns 129 shares of the company’s stock valued at $63,000 after buying an additional 23 shares during the last quarter. Sovereign Financial Group Inc. boosted its stake in IDEXX Laboratories by 5.1% in the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company’s stock valued at $237,000 after acquiring an additional 23 shares during the period. Mather Group LLC. grew its holdings in shares of IDEXX Laboratories by 3.9% during the third quarter. Mather Group LLC. now owns 617 shares of the company’s stock valued at $312,000 after purchasing an additional 23 shares during the last quarter. Angeles Wealth Management LLC raised its position in shares of IDEXX Laboratories by 2.4% during the 3rd quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company’s stock worth $545,000 after purchasing an additional 25 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of IDEXX Laboratories by 3.5% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 761 shares of the company’s stock worth $371,000 after purchasing an additional 26 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.11% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. JPMorgan Chase & Co. lowered their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays reduced their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $539.63.

IDEXX Laboratories Stock Down 0.4 %

IDXX opened at $409.03 on Friday. The stock’s fifty day moving average is $435.18 and its 200-day moving average is $469.56. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a market capitalization of $33.49 billion, a PE ratio of 39.44, a P/E/G ratio of 3.99 and a beta of 1.37. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period in the prior year, the company earned $2.53 EPS. IDEXX Laboratories’s revenue was up 6.6% on a year-over-year basis. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.